LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom … Continue reading “Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019”
ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical Company Limited … Continue reading “ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology”
The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type … Continue reading “ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank”
• Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. • The two companies will leverage their combined scientific, commercial and market access expertise to … Continue reading “GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer”
Castor establishes new US operations, building on leadership position across the EU Amsterdam, The Netherlands and Hoboken, New Jersey, USA, October 7, 2019: Castor, a health-tech company that helps medical … Continue reading “Castor Announces International Expansion to Meet Growing Demand for an AI-Powered Clinical Data Platform”
Novel deep-learning approach for predicting and explaining the key prognostic factors for patients with Mesothelioma Paris, France and New York, USA, October 7th, 2019 – Owkin, which is developing machine … Continue reading “Owkin publishes breakthrough research in Nature Medicine”
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company’s lead compound Nefecon, … Continue reading “Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon”
Further strengthens position in oncology; investment in STipe increases oncology portfolio to six companies Dr Christian Schetter, Entrepreneur in Residence at Arix Bioscience, joins STipe as Executive Chairman LONDON, 30 … Continue reading “Arix co-leads EUR 20 million Series A investment round for STipe Therapeutics”
Date September 30, 2019 Location Copenhagen STipe funded through Novo Seeds’ company building efforts First company out of BioInnovation Institute, a new Novo Nordisk Foundation initiative Novo Seeds, the company … Continue reading “Novo Seeds co-leads €20 Million Series A Financing in STipe Therapeutics”
OMO-1 has potential to treat cancer as a monotherapy and in combination with EGFR TKIs for patients becoming resistant to or progressing on treatment Beerse, Belgium, 25 September 2019 – … Continue reading “OCTIMET expands ongoing proof of concept study to evaluate the combination of highly selective MET Kinase Inhibitor OMO-1 with EGFR TKIs”
Cambridge, UK and New York, US, 24 September 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today … Continue reading “Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States”
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today provides a business update for the last twelve months. Following the rebranding of … Continue reading “Neuraxpharm provides business update on a transformational year”
Data to be presented at inaugural STORM Therapeutics RNA Epigenetics in Human Disease Conference in Cambridge, UK 18 September 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the … Continue reading “STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes”
Enables development of first-in-class molecular radiotherapy based on PARP inhibitor Offers significant potential for diagnosing and treating a broad range of cancers LONDON, UK, 05 September 2019 – Theragnostics, which … Continue reading “Theragnostics signs agreement with Astrazenenca”
To accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM WAVRE, Belgium — 5 September 2019: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the … Continue reading “iSTAR Medical announces EUR 40m Series C Financing”
Los Angeles, September 4, 2019 – ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and / or present at the following investor and scientific … Continue reading “ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019”
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has obtained written feedback from the US Food and Drug Administration (FDA) that will have a significant impact on the ongoing … Continue reading “Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study”
Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis … Continue reading “Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219”
20 August 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapeutics modulating RNA epigenetics, today announced that it will be hosting an … Continue reading “STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com